Tandem Diabetes Care Charts Growth Amid Transition

Tandem Diabetes Care ((TNDM)) has held its Q1 earnings call. Read on for the main highlights of the call.

Tandem Diabetes Care’s latest earnings call struck an upbeat tone, underscoring record pump shipments, expanding margins, and positive cash generation, even as management acknowledged some near-term friction. Executives highlighted a strengthened balance sheet and a robust product roadmap, arguing that these positives outweigh temporary supply constraints and the early challenges of shifting customers to the new PayGo pharmacy model.

Record Shipments and Sales Momentum

Tandem delivered a record first quarter with more than 29,000 insulin pump shipments worldwide and $247 million in sales, underscoring strong demand for its technology. U.S. volumes exceeded 19,000 pumps, up about 10% year over year, with $161 million in revenue, while renewals made up over half of shipments and roughly two-thirds of new starts came from multiple daily injection users.

Margin Expansion and Path Toward Profitability

Profitability trends improved sharply as gross margin climbed to 55%, nearly five points higher than a year ago and the best first-quarter level in the company’s history. Adjusted EBITDA reached about 1% of sales, boosted by an IPR&D comparison, while operating margin improved by around 40 percentage points to negative 7%, signaling a clearer path toward sustained profits.

Cash Generation and Balance Sheet Strength

The company generated $5 million of free cash flow and ended the quarter with $570 million in cash and investments, giving it ample strategic flexibility. Tandem also completed a zero-coupon convertible debt financing in February, raising net proceeds of $276 million, which management emphasized as a key step in fortifying the balance sheet without increasing interest burden.

Early Progress with Pharmacy PayGo Model

Tandem launched its PayGo offering in the pharmacy channel in March, quickly securing about 40% formulary coverage and driving pharmacy to roughly 6% of U.S. sales in the quarter. While still small, the early adoption is tracking in line with internal plans, and management reiterated confidence that PayGo will scale over time and enhance the recurring revenue profile.

International Go-Direct Expansion

The company continued to shift its international business toward a direct-to-customer structure, launching commercial operations in the U.K., Switzerland and Austria. International shipments surpassed 10,000 pumps and sales reached $86 million, up 3% year over year, with direct channel sales rising to about 11% of the international mix from less than 5% previously.

Product and Technology Milestones

On the innovation front, Tandem expanded access to its Mobi pump by enabling Android support in the U.S. and secured clearance for Control-IQ+ in pregnancy, the first automated insulin delivery system cleared for this use domestically. The company is preparing to roll out FreeStyle Libre 3+ integration in select European markets in the second quarter, update Dexcom G7 compatibility, and begin commercial launches of Mobi outside the U.S.

Pipeline: Mobi Tubeless and Closed-Loop Pivotal

Tandem is advancing its next wave of products, planning a second-quarter 510(k) filing for Mobi Tubeless, its first tubeless pump with extended-wear technology. Management also reaffirmed plans to start a pivotal study for its fully closed-loop system later this year, positioning the company to compete more aggressively in next-generation automated insulin delivery.

Infusion Set Supply Constraints

Despite the strong quarter, capacity issues at a key infusion set supplier that began late last year continued to affect some customers and modestly pressured infusion set revenue. The company expects this headwind to last another quarter or two but anticipates gradual improvement into the second half as supply ramps.

PayGo Transition Growing Pains

The early PayGo rollout carried near-term costs, with management citing roughly a $1 million impact in the first quarter as processes and workflows were adjusted. Adoption is still nascent, with fewer than 5% of customers ordering pumps and supplies through the pharmacy channel so far, but the company views these operational hurdles as temporary.

International Timing and One-Off Effects

International results were influenced by several timing and non-recurring factors, including favorable currency and a one-time Swiss accounting benefit that lifted first-quarter sales. At the same time, expected go-direct headwinds of $3 million to $4 million shifted into the second quarter, and year-over-year comparisons are clouded by a prior-year distributor timing benefit of roughly $5 million.

Seasonality and New-Start Dynamics

New pump starts dipped slightly both year over year and sequentially in the first quarter, a trend management attributed largely to typical seasonal patterns. Executives expect this softness to reverse later in the year as new products gain traction and pharmacy-based access improves, which could expand the funnel of new customers.

Friction in Converting Existing Users to Pharmacy

Shifting compliant DME customers to the pharmacy model has proven slower than hoped due to the need for new prescriptions and added physician engagement. While pharmacy can lower out-of-pocket costs for many patients, these extra steps are creating near-term friction that is expected to ease as stakeholders adjust to the new workflow.

Uncertain Timing of New Product Commercialization

Although Tandem expects to file for Mobi Tubeless clearance in the second quarter and sees potential approval in the back half of the year, executives stressed that exact timing remains uncertain. The company is not baking meaningful 2026 revenue from the product into its outlook and plans to phase commercialization carefully to avoid disrupting existing operations.

Guidance and Forward Outlook

Management reaffirmed 2026 guidance for worldwide sales of $1.065 billion to $1.085 billion, including $730 million to $745 million in the U.S. and $335 million to $340 million internationally, alongside full-year gross margins of 56% to 57% and adjusted EBITDA of 5% to 6%. For the near term, Tandem expects second-quarter sales of about $255 million, with margins similar to the first quarter, and has incorporated modest infusion-set and go-direct headwinds as well as ongoing PayGo adoption into its assumptions.

Tandem’s earnings call painted a picture of a company balancing tactical growing pains with strategic progress and accelerating scale. Record shipments, improving profitability metrics and a healthy balance sheet, paired with a robust innovation pipeline, left management confident that temporary supply and transition issues will give way to sustained growth, a message likely to resonate with investors tracking the diabetes technology space.